NASDAQ: ELVN

Enliven Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for ELVN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Enliven Therapeutics, Inc. (NASDAQ: ELVN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 14:09 UTC.

Key facts

Charts

Charts are in the appInteractive charts for ELVN are available in Oxford Ledge.
Open ELVN in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

8-KEntry into material agreement; Regulation FD disclosure; Financial statements and exhibits2026-06-12↗
8-KRegulation FD disclosure; Other material event; Financial statements and exhibits2026-06-11↗
8-KAmendments to articles or bylaws; Shareholder vote results; Financial statements and exhibits2026-06-10↗
10-QQuarterly financial report (unaudited)2026-05-07↗
8-KResults of operations / financial condition; Financial statements and exhibits2026-05-07↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-16

2026-10-16DirectorStock Option (right to buy)Award23,394—
2026-10-05DirectorOption exercise13,000$201.1K
2026-10-05DirectorSale-13,000$606.7K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

FMR LLC10,025,017$508.77M+50.5%
ORBIMED ADVISORS LLC6,776,632$343.91M-14.9%
Polar Capital Holdings Plc6,430,636$326.35M+26.9%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-12-11Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-05-29Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersKunkel's BoardEstimatedSEC 8-K →
2023-03-01AuditorChanges in registrant's certifying accountantDeloitteEstimatedSEC 8-K →

Company news

View all →

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
prnewswire.com2026-10-14
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga2026-10-02POS
Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha Feed2026-09-16
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
fool.com2026-06-27POS
Enliven Therapeutics: Continuing The Pop Off; What Could Go Wrong?
Seeking Alpha Feed2026-06-22

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ELVN and 5,000+ tickers.

Create a free account — keep ELVN

For your agent

GET /api/data?ticker=ELVN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt